Reacting to Novo Nordisk's lawsuit: An attack on millions of Americans
Hims & Hers has responded to Novo Nordisk's patent infringement lawsuit, calling it an attack on American consumers after launching a non-approved version of the drug Wegovy.
Fosun Pharma’s US$1.55 billion Eisai deal signals shift to long-term partnerships
Fosun Pharma has signed a US$1.55 billion licensing deal with Japan's Eisai for a cancer drug, indicating a trend towards long-term partnerships in the global pharmaceutical industry.